## Mechanism: 
- human IgG1 monoclonal antibody bDMARD: 
	- selectively binds to IL-17A cytokine ➔ inhibiting IL-17A interaction with the IL-17A receptor. ➔ inhibiting inflammatory and immune responses. 
## Indications: 
- inflammatory and immune responses, rheumatoid arthritis. 
## Adverse Effects: 
- infection, inflammatory, and immune responses, exacerbate inflammatory bowel disease